[4] This may mean that dietary supplementation can be helpful, while an individual learns to manage their diet as they adjust to the medications
View the current CareBareRX program options (official CareBareRX page) How CareBareRX Compares to What the GLP-1 Telehealth Category Typically Offers Given how crowded the telehealth weight loss space has become in 2026, context helps
Lingvay I, Brown-Frandsen K, Colhoun HM, Deanfield J, Emerson SS, Esbjerg S, Hardt-Lindberg S, Hovingh GK, Kahn SE, Kushner RF, et al
Tirzepatide is the only licenced GLP-1/GIP co-agonist for obesity, with several more GLP-1/GIP co-agonists in development [15]